Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Apsen pays Nestle $215M for infant formula market licenses; UAS Labs acquired in private equity deal; health groups urge Sebelius to follow OTC Plan B order; Abbott continues emerging markets push; more news In Brief.

You may also be interested in...



Supplement Sector Private Equity, M&A Activity Set For 2014 Uptick

Merger and acquisition activity is expected to rise in the supplement sector 2014, says Andre Guardi of consultancy Moss Adams LLC. Companies maturing to ”critical mass” for acquisition, international and big pharma buyers, and interest in ingredient firms are all predicted to drive M&A upward in 2014.

Supplement Sector Private Equity, M&A Activity Set For 2014 Uptick

Merger and acquisition activity is expected to rise in the supplement sector 2014, says Andre Guardi of consultancy Moss Adams LLC. Companies maturing to ”critical mass” for acquisition, international and big pharma buyers, and interest in ingredient firms are all predicted to drive M&A upward in 2014.

Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio

Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel